Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: June 27, 2022


✉ Email this page to a colleague

« Back to Dashboard

When do Escitalopram Oxalate patents expire, and what generic alternatives are available?

Escitalopram Oxalate is a drug marketed by Mylan Pharms Inc, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Lannett Co Inc, Macleods Pharms Ltd, Taro, Accord Hlthcare, Cadila, Graviti Pharms, Hikma Pharms, Invagen Pharms, Jubilant Generics, Lupin Ltd, Mylan, Pharm Assoc, Prinston Inc, Teva Pharms Usa, and Torrent Pharms Ltd. and is included in twenty-three NDAs.

The generic ingredient in ESCITALOPRAM OXALATE is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Escitalopram Oxalate

A generic version of ESCITALOPRAM OXALATE was approved as escitalopram oxalate by AMNEAL PHARMS on March 14th, 2012.

  Try it Free

Drug patent expirations by year for ESCITALOPRAM OXALATE

See drug prices for ESCITALOPRAM OXALATE

Drug Sales Revenue Trends for ESCITALOPRAM OXALATE

See drug sales revenues for ESCITALOPRAM OXALATE

Recent Clinical Trials for ESCITALOPRAM OXALATE

Identify potential brand extensions & 505(b)(2) entrants

NYU Langone HealthPhase 4
National Institute on Aging (NIA)Phase 4
Xijing HospitalN/A

See all ESCITALOPRAM OXALATE clinical trials

Paragraph IV (Patent) Challenges for ESCITALOPRAM OXALATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LEXAPRO Capsules escitalopram oxalate 5 mg 021323 1 2005-08-17
LEXAPRO Capsules escitalopram oxalate 10 mg and 20 mg 021323 1 2005-03-30

US Patents and Regulatory Information for ESCITALOPRAM OXALATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan ESCITALOPRAM OXALATE escitalopram oxalate TABLET;ORAL 077550-001 May 14, 2015 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Jubilant Generics ESCITALOPRAM OXALATE escitalopram oxalate TABLET;ORAL 202280-001 Sep 12, 2012 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Prinston Inc ESCITALOPRAM OXALATE escitalopram oxalate TABLET;ORAL 078032-003 Aug 28, 2015 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.